Atomoxetine Pharmacogenetics: Associations with Pharmacokinetics, Treatment Response and Tolerability
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder and is predominantly metabolized by the CYP2D6 enzyme. Differences in pharmacokinetic parameters as well as clinical treatment outcomes across CYP2D6 genotype groups have resulted in dosing recommendations within the product label, but clinical studies supporting the use of genotype guided dosing are currently lacking. Furthermore, pharmacokinetic and clinical studies have primarily focused on extensive as compared with poor metabolizers, with little information known about other metabolizer categories as well as genes involved in the pharmacodynamics of atomoxetine. This review describes the pharmacogenetic associations with atomoxetine pharmacokinetics, treatment response and tolerability with considerations for the clinical utility of this information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Arnsten, A. F. T. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050084013 · Cited by 458
PLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Faraone, S. V., & Glatt, S. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04902pur · Cited by 387
Arnsten, A. F. T., & Pliszka, S. R. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.020 · Cited by 383
Stimulant treatment over five years: adherence, effectiveness, and adverse effects
Charach, A., Ickowicz, A., & Schachar, R. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200405000-00009 · Cited by 315
Delayed pharmacological effects of antidepressants
Frazer, A., & Benmansour, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001015 · Cited by 160
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
NICE guideline: attention deficit hyperactivity disorder: Figure 1
Atkinson, M., & Hollis, C. (2010) · Archives of disease in childhood - Education & practice edition · doi:10.1136/adc.2009.175943 · Cited by 97
Cited by
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., et al. (2019) · Pediatrics · doi:10.1542/peds.2019-2528 · Cited by 1,562
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Pharmacogenomic Biomarkers and Their Applications in Psychiatry
Kam, H., & Jeong, H. (2020) · Genes · doi:10.3390/genes11121445 · Cited by 37
“Although atomoxetine has a wide therapeutic window, CYP2D6 poor metabolizers or patients who are taking a CYP2D6 inhibitor, such as paroxetine, fluoxetine, and quinidine, may benefit from improved therapeutic outcomes or suffer from an increased risk of adverse effects [88,90].”
BackgroundNonstimulant Treatments for ADHD
Newcorn, J. H., Krone, B., & Dittmann, R. W. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.005 · Cited by 29
Metadata
- Authors
- Brown, J. T., & Bishop, J. R.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2015-08
- Volume
- 16
- Issue
- 13
- Pages
- 1513-1520
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2208367373
- Cited by
- 18
- References
- 11
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.